Oritavancin: One And Done Antibiotic Could Reduce MRSA
Methicillin-resistant Staphylococcus aureus (MRSA) has become the poster child for antibiotic resistance in large part because of a larger problem: patients tend to stop taking antibiotics once they feel better. In such instances, the surviving bacteria may become impervious to the drugs designed to fight them.
A single-dose antibiotic could fix that and a new one, oritavancin, is as effective in the battle against stubborn skin infections as a twice-daily infusion given for up to 10 days, according to a recent large study.
The three-year study of oritavancin that encompassed two…